It's November 8th, 203rd,000,

it's November 8th, 2023 at Eli Lilly's headquarters in Indianapolis.

David Ricks, Eli Lilly's CEO, is speaking with reporters.

Ricks smiles.

He's here to make an announcement he thinks will finally give Eli Lilly the upper hand

against OZempic maker Novo Nordisk.

As of this morning, the FDA has given its approval for Zepbound.

Zepbound is Eli Lilly's once weekly weight management drug, and this approval means the company

can officially enter the GLP1 weight loss battle.

Novo Nordisk has had a more than two-year head start with their GLP1 weight loss drug Wegovi,

but Zepound could change the game for Lilly. Ricks continues.

We know there's a large group of Americans waiting for answers, and Zepbound has the highest

efficacy we've seen in an approved drug so far. Did you catch that? Studies show that Zepbound

is actually more effective than Wigovee for weight loss.

Later studies confirmed that patients lost around 20% of their body weight on Zepbound,

compared to around 13% on Wigofi. That might seem like a small difference, but this 7%

could supercharge Eli Lilly's position in the market.

Rix goes on to explain that Zepbound doesn't just mimic the GLP1 hormone like Wigovi's

semaglutide does.

Zepbound's active ingredient, terseptide, also mimics an insulin hormone called GIP, which not only helps curb your appetite,

but is believed to help the body process sugar and fat more efficiently as well.

This dual-pronged approach gives Zepbound the edge in weight loss.

...